What Idipharma does

Idipharma (legal name: IDI Integratori Dietetici Italiani S.r.l.) is an Italian nutraceutical and medical device company founded in 1997 by pharmacist Dr. Pietro Bottino in Aci Bonaccorsi, Sicily. The company develops, manufactures, and distributes patented dietary supplements and CE-marked medical devices across four therapeutic verticals: urology (prostate health, prostatitis), gynecology (PCOS, vaginitis, pregnancy nutrition), fertility (male and female reproductive health), and sexuality (female intimate wellness). Its technology base centers on proprietary formulations combining botanical extracts (Serenoa repens, Ajuga reptans, flower pollen extracts from Graminex, Myo-inositol, Crocus sativus) with patented drug delivery platforms, including triple-layer controlled-release tablets (Spergin Q10) and modified-release double-layer tablets (Morfolic). Multiple products hold international patents or have patents pending (XIPAG, Miclosit-HA, Idiprost Gold, Tiagin, Spergin), and Deprox 500 is included in European Association of Urology guidelines for prostatitis treatment.

The company operates a hybrid B2B/B2C commercial model. Primary go-to-market is direct specialist detailing through a network of scientific representatives — 90% holding scientific university degrees — who engage urologists and gynecologists across Italy. Distribution extends internationally since 2016 through country-level distributors for DEPROX and REFEEL product lines, with the export department providing regulatory, training, and marketing support. Consumer-facing channels include pharmacy distribution in Italy and partner e-commerce platforms (b2store.it, tryrefeel.com). Marketing leverages international conference participation (Vitafoods, Arab Health, CPHI), specialist educational events held at the Catania-area headquarters, and a LinkedIn corporate presence.

Idipharma is privately held under founding family ownership with no disclosed institutional investors, venture capital, or private equity backing. The company employs 11-50 people and currently operates under second-generation leadership with Alessandro Bottino as CEO. Revenue is not publicly disclosed. Certifications include ISO 9001 (2018), ISO 13485 (2018) for medical device quality management, and Gender Equality Certification (UNI PDR 125:2022, 2025). The strategic posture emphasizes incremental portfolio expansion within existing specialty verticals, deepening clinical evidence through research grants and guideline inclusion, and selective international expansion via distributor partnerships rather than capital-intensive market entry.

Name

Idipharma

Legal name

IDI Integratori Dietetici Italiani S.r.l.

Website

https://idipharma.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

11–50 employees

Short description

Idipharma is an Italian pharmaceutical company that develops and manufactures patented nutraceuticals and CE-marked medical devices for urology, gynecology, fertility, and female sexual health, selling through a scientific representative network targeting specialists in Italy and international distributors abroad.

Ownership category

akta.pro rank

Product category

Nutraceuticals and Medical Devices

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Herbal & Botanical Supplements (CRADAGAD)

akta.pro secondary industries

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Women’s Health Supplements (Prenatal, Menopause, Hormonal) (CRADAGAK), Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin) (AFAJAKAK)

Keywords

• Nutraceutical supplements
• Medical devices
• Urology products
• Gynecology products
• Fertility supplements

Headquarters

HQ city

Aci Bonaccorsi

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Nutraceutical products: Idipharma manufactures and sells nutraceutical supplements including Spermagin, Fertiplus, Spergin, FT500, Deprox, Idiprost, and XIPAG products for urology, gynecology, and fertility applications. Products are distributed through pharmacies and directly to healthcare specialists.
2. Medical devices: The company produces medical devices including gynecological products (Tiagin, Clositol, Amnios, Endox), urological products (Deprox suppositories, Peonil), and sexual health products (Refeel cream and spray).
3. International export: Since 2016, Idipharma exports products internationally through distribution partnerships. The company is present in many countries and seeks additional distributors for Deprox and Refeel product lines.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels3 records

Core offering

Idipharma develops, manufactures, and commercializes a portfolio of patented nutraceutical dietary supplements and CE-certified medical devices focused on four therapeutic areas: urology (prostate health, prostatitis), gynecology (PCOS, vaginal health, pregnancy nutrition), couple fertility (male and female reproductive health), and female sexuality. Products are sold under proprietary brands including Deprox, Idiprost, XIPAG, Spergin, Tiagin, Refeel, and Clositol, with several formulations protected by international patents.

Product overview

Idipharma is a nutraceutical and medical device company with a portfolio organized across four therapeutic areas: Urology, Gynecology, Fertility, and Sexuality. The product portfolio is not a single unified platform but a collection of distinct branded products spanning dietary supplements (nutraceuticals) and medical devices. In Urology, the core products are Deprox® 500/HP/Supposte, Idiprost®/Idiprost® Gold, XIPAG® (patented Ajuga reptans + pollen extract formulation), and Peonil® crema-gel. In Gynecology, products include Amnios®, Clositol®/Clositol® G75, Endox® Supposte, MICLOSIT®-HA (patented), Morfolic® (food for special medical purposes), NutriMamma®, Tiagin® fast/schiuma (both patented medical devices), and Morlen® (dermo-cosmetic serum). The Sexuality line is centered on the Refeel® brand (compresse, crema, spray) containing Visnadin and adaptogens. The Fertility line covers both male (Spergin® Q10/Forte) and female (Fertiplus® SOD, FT500® Plus, Morfolic®) reproductive health. Multiple products are protected by international patents or have patents pending (XIPAG®, MICLOSIT®-HA, Tiagin® line). Several products carry CE medical device certification and have been clinically tested, with some (e.g., Deprox® 500) included in European Association of Urology (EAU) guidelines.

Differentiator

Problem solved

Functional benefit

Products and services

• Deprox 500 Dietary supplement based on flower pollen (Graminex G63) with B vitamins (Riboflavin, Cobalamin, Pyridoxine, Thiamine, Niacin, Folic Acid), used as adjuvant in the treatment of prostatitis. Clinically tested on men with chronic pelvic pain associated with prostatitis and included in European Association of Urology (EAU) guidelines.
• Deprox HP Dietary supplement based on flower pollen extract (Graminex G60, Graminex NAX) with high ORAC value, providing protective action against oxidative stress, indicated in conditions of altered homeostasis contributing to inflammatory processes.
• Deprox Supposte Medical device (CE 0476) indicated as adjuvant in the treatment of local symptoms (burning, pain) in the anorectal area due to congestive phenomena associated with acute and chronic prostatitis.
• Idiprost Dietary supplement containing Zinc with Lutein and oil extract of Serenoa repens, supporting the functionality of the prostate and urinary tract. Serenoa repens acts on the enzyme 5-alpha-reductase involved in testosterone-to-dihydrotestosterone conversion.
• Idiprost Gold Dietary supplement based on Serenoa repens and Crocus sativus (saffron), contributing to improvement of prostate gland processes and supporting functionality of prostate and urinary tract through the synergistic action of its components. Covered by international patent.
• XIPAG Idipharma patented dietary supplement based on Ajuga reptans extract (Teupolioside) and Graminex G96 flower pollen extract, for adjuvant treatment of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Clinically tested in multiple clinical studies and recipient of the ISCPB&S Best Oral Presentation Award in the NOVELTY category.
• Peonil crema-gel Medical device (CE 0477) indicated as adjuvant in natural repair of uncomplicated post-surgical lesions and as adjuvant in treatment of bacterial, fungal, and viral infections.
• Amnios Medical device (CE 0843) for vaginal dryness and atrophy, part of the gynecological product line addressing female intimate health.
• Clositol Dietary supplement based on Myo-inositol with gymnemic acids (from Gymnema Sylvestre), Vitamins C and E, and methylfolate, for women of reproductive age (normal-weight patients without risk factors, aged under 40), used as adjuvant in polycystic ovary syndrome (PCOS).
• Clositol G75 Dietary supplement based on Myo-inositol (2000 mg), gymnemic acids, Vitamins C and E, and methylfolate, for women of reproductive age (overweight/obese patients grade I), useful as adjuvant in PCOS, type II diabetes, metabolic syndrome, insulin resistance and hyperinsulinemia. Clinically tested on women with PCOS.
• Endox Supposte Medical device for gynecological applications, addressing symptoms related to vaginal and cervical conditions.
• MICLOSIT-HA Dietary supplement with patent filed by Idipharma, based on Ajuga reptans extract, micronized Gymnema (Microgym), micronized Myo-inositol (Microsit), and folate as methylfolate. Supports metabolism of carbohydrates, lipids, and homocysteine; used as adjuvant in PCOS.
• Morfolic Food for special medical purposes containing L-methylfolate (biologically active form of folic acid) and Vitamin C, for subjects deficient in folate (including those with MTHFR enzyme mutations) who cannot restore normal folate and homocysteine levels through diet or supplements. Indicated for couple fertility and positive pregnancy outcomes. Delivered via double-layer modified-release tablet technology.
• NutriMamma Dietary supplement of vitamins, minerals, DHA, lutein and folate (as L-methylfolate), for use during pregnancy and breastfeeding. The biologically active form of folate is readily absorbed and distributed to all tissues without requiring biotransformation.
• Tiagin fast Medical device (CE 0477) vaginal softgels with innovative patented formulation, adjuvant in vaginitis/vaginosis treatment and vulvar discomfort management.
• Tiagin schiuma Medical device (CE 0477) vulvar foam with innovative patented formulation, coadiuvant in vaginitis/vaginosis and treatment of vulvar discomfort.
• Morlen Dermo-cosmetic serum for intimate well-being with six natural active ingredients (D-Panthenol, Azelaic Acid, Phytosterols from Cardiospermum Halicacabum, Bisabolol, Hyaluronic Acid from bacterial fermentation, Vitamin E from Sunflower). Provides soothing, hydrating, protective and regenerative action for sensitive vulvar skin and mucous membranes.
• Refeel compresse Dietary supplement based on Muira puama and Apple, with Schisandra chinensis and Rhodiola rosea providing tonic-adaptogenic effects, for female sexual wellness.
• Refeel crema Medical device (CE 0476) for female sexual health, formulated with Visnadin to maintain firmness and tone of external female genitalia.
• Refeel spray External spray formulation based on Visnadin (from Ammi visnaga plant), applied to external female genitalia to maintain turgescence and tone. Available in 20 ml milky liquid format for external use.
• Spergin Q10 Dietary supplement based on L-Arginina, L-Carnitina, L-Ornitina, L-Citrullina, Vitamin E with Coenzyme Q10 and Zinc, contributing to normal fertility and reproduction. Triple-layer controlled-release tablets (Patented Technology) for male idiopathic infertility.
• Spergin Forte Dietary supplement based on L-Arginina (2500 mg), Coenzyme Q10 (200 mg), Taurina (500 mg), Vitamin C (180 mg), and Zinc (1.5 mg), contributing to normal fertility and reproduction in males.
• FT500 Plus Dietary supplement for female infertility, containing a combination of principles with proven scavenger effect on radical species for oxidative stress management, with added Myo-Inositol in the Plus formulation.
• Fertiplus SOD Dietary supplement for fertility support, part of the fertility product line addressing both male and female reproductive health with clinically documented formulations.

Quantifiable outcome

• Deprox 500 included in European Association of Urology (EAU) guidelines for prostatitis treatment
• +1 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Società Italiana di Urologia (SIU)minorStrategic or Co-development Partner · 1 January 2024Collaboration with SIU to fund three research grants of €5,000 each for studies on XIPAG efficacy in treating benign prostatic hyperplasia. This partnership supports clinical research and strengthens credibility in the urology specialist community.
• International Distribution PartnerscoreChannel Partner/ Reseller/ Distributor · 1 January 2016Since 2016, Idipharma has established partnerships with distributors in multiple countries for export of DEPROX and REFEEL product lines. Partners receive training, marketing support, and regulatory assistance from Idipharma's export department for product registration and promotion in their territories.
• Graminex LLCcoreTechnology or IntegrationLicensing partnership for use of Graminex flower pollen extracts (G96, G60, G63, NAX) in Idipharma's urology products including XIPAG, Deprox 500, and Deprox HP. Graminex extracts are standardized bioactive ingredients with documented clinical efficacy in prostate health applications.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Sofar: Italian nutraceutical company of similar scale headquartered near Milan, focused on probiotics, urological, and gynecological supplements. Closest comparable peer given Italian heritage, comparable product mix (botanical/urology supplements, gynecology), and shared specialist detailing GTM.
• Uriach (Laboratorios Uriach): Spanish specialty pharma/OTC company with a strong botanical supplements portfolio including urology and women's health products. Comparable mid-size European specialty company with nutraceutical-and-medical-device mix and similar GTM through pharmacy and specialist channels.
• Theramex: Specialty pharmaceutical company focused exclusively on women's health, including fertility, contraception, and menopause. Direct overlap with Idipharma's gynecological and fertility product lines, targeting the same specialist prescriber channels.
• Exeltis: Specialty pharma focused on women's health and dermatology across multiple European and Latin American markets. Comparable mid-size European player with women's health fertility/intimate care products distributed through gynecologist channels.

Broad incumbents

• Italfarmaco: Italian specialty pharmaceutical company with established women's health and gynecology franchises (including fertility and intimate health). Broader product portfolio but directly overlaps with Idipharma's gynecological and reproductive-health categories, particularly in Italy.
• Recordati: Major Italian specialty pharmaceutical company with a leading urology franchise (treatment of BPH and LUTS). Operates at significantly larger scale but competes for the same specialist prescriber base and condition categories as Idipharma in urology.
• Organon: Global women's health specialty pharma (spun out of Merck) with established fertility, gynecology, and reproductive medicine franchises. Operates at global scale but competes in the same specialist prescription categories for fertility and reproductive health.
• Zambon: Italian pharmaceutical company with established women's health and respiratory franchises, plus consumer health lines. Overlaps with Idipharma on Italian market presence, women's health, and physician-detailing GTM, although at larger scale and broader portfolio.
• Gedeon Richter: Hungarian-headquartered specialty pharma with established women's health, gynecology, and reproductive medicine portfolios across Central and Eastern Europe. Regional overlap with Idipharma's intended international expansion geographies in CEE.

Emerging players

• Duchesnay: Canadian specialty pharma focused on women's health and pregnancy (e.g., nausea management, prenatal care). Comparable niche women's-health positioning including pregnancy supplements that overlap with Idipharma's NutriMamma line, though smaller scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/idipharma
• Xx.com/idipharma
• Facebookfacebook.com/idipharma

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Idipharma